Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 164

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 4A
Chunk 164
---
                
           of March 17, 2025, of which options to purchase the following number of shares expire on the following dates, respectively: 1,800 on September  
           15, 2032, 1,800 on May 11, 2033 and 1,350 on June 13, 2034. The weighted average exercise price of these options is NIS 28.42 per ordinary      
           share.                                                                                                                                          
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  (7)      Consists of 7,450 ordinary shares issuable upon exercise of options that are currently exercisable or exercisable within 60 days            
           of March 17, 2025, of which options to purchase the following number of shares expire on the following dates, respectively: 2,500 on April  
           20, 2030, 1,800 on September 15, 2032, 1,800 on May 11, 2033 and 1,350 on June 13, 2034. The weighted average exercise price of these       
           options is $8.90 per ordinary share.                                                                                                        
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  (8)      Consists of 8,250 ordinary shares issuable upon exercise of options that are currently exercisable or exercisable within 60 days               
           of March 17, 2025, of which options to purchase the following number of shares expire on the following dates, respectively: 1,000 on December  
           23, 2028, 250 on February 1, 2030, 250 on February 1, 2031, 1,800 on August 10, 2031, 1,800 on September 15, 2032, 1,800 on May 11, 2033       
           and 1,350 on June 13, 2034. The weighted average exercise price of these options is $16.15 per ordinary share.                                 
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  (9)      Includes 83,886 ordinary shares held by Mr. Recanati. Also includes 8,437 ordinary shares issuable upon exercise of options that         
           are currently exercisable or exerc